Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive secures US$1.4mln from US defence department for biohazard-detection device

Genedrive is further developing its handheld device to detect a broader range of biohazard targets
Genedrive
The device has had successful field trials

Genedrive PLC (LON:GDR) has secured a further US$1.4mln in funding from the US Department of Defence for its handheld biohazard-detection device programme.

The extra funding follows successful field trials on the portable device whereby officials assessed its potential to check for hazards such as biological warfare agents.

Genedrive will use the funds to further develop the device to detect a broader range of biohazard targets across multiple cartridges.

READ: Genedrive making “good progress” as revenues rise across board, Hep-C assay nears EU approval

The company said the aim of the programme is to develop a “cost-effective system that would allow multiple units and tests to be deployed for field use”.

The latest funding brings the total it has received from the Department of Defence to US$6.5mln.

The next stage of the programme is expected to generate about US$1.4mln in development income for the year to 30 June 2018.

"This next phase of field testing will help to further validate and confirm the characteristics of the Genedrive system: portability, flexibility and accuracy,” said Genedrive’s chief executive, David Budd.

 “The evaluation will be far reaching, rigorous and, if successful, it will be a clear validation of the Genedrive unit as a robust and easily deployable hand held device for pathogen and disease detection."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

test tubes in a laboratory
November 01 2017
If you’re a pharmacist looking to get your hands on an unlicensed drug, there’s a good chance Clinigen can help
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Cancer cells
September 05 2017
In an initiation note on the company, finnCap’s analysts noted that ANGLE is focused on the development of Parsortix, an instrument platform with recurring revenues designed to isolate and harvest rare circulating tumour cells from a patient’s blood sample

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use